RSV

Latest News
May 14th 2025

Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use

February 19th 2025

Nirsevimab, RSVpreF Saw High Uptake With No Preterm Risk for RSVpreF

November 24th 2024

Low RSV Vaccination Rates in Nursing Homes Highlight Urgent Need for Uptake

November 22nd 2024

In-Room Air Purifiers Could Impact RSV Incidence Among Older Adults

November 20th 2024

Community Pharmacies Hold Key Role in Protecting Older Adults From RSV

Video Series
View All
August 5th 2024

Key Takeaways on RSV Vaccination

August 5th 2024

Improving RSV Vaccination Rates and Addressing Misinformation

August 5th 2024

Improving Insurance Coverage for RSV Vaccines

July 29th 2024

Current and Potential Obstacles Related to Administering RSV Vaccines

July 29th 2024

Identifying Patients Eligible for RSV Vaccine

July 22nd 2024

Addressing Vaccine Fatigue

July 22nd 2024

The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

July 15th 2024

Financial and Clinical Benefits of RSV Immunization

July 15th 2024

Shared Decision-Making Practices in RSV

July 8th 2024

Increasing Awareness of RSV Vaccines in At-Risk Patients

Video Interviews
View All
August 29th 2023

Dr Joseph Aracri Discusses Severity, Protection for Coming RSV Season

August 23rd 2023

Dr Joseph Aracri Discusses RSV in Infants

More News

Blood sample tube for RSV test. | Image credit: JUN LI - stock.adobe.com
November 15th 2024

RSV Vaccine Proven Effective in Reducing RSV-Related Hospitalizations

Kennedy Ferruggia
Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.
RSV, COVID, Flu vaccines. | Image credit: angellodeco - stock.adobe.com
November 14th 2024

Impact of RSV on Hospitalizations in US Adults Prior to Vaccine Introduction

Pearl Steinzor
Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 years and older.
RSV vaccine vial with syringe - Respiratory syncytial virus shot | MargJohnsonVA - stock.adobe.com
October 23rd 2024

GSK's Arexvy Vaccine Shows Strong Efficacy Against RSV in Older Adults

Sophia Abene
The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus (RSV)-related lower respiratory tract disease in older adults over 3 seasons.
respiratory infection. | Image credit: Kateryna - stock.adobe.com
October 21st 2024

Clinical Outcomes, Mortality Risk Factor of RSV, Influenza in Hospitalized Adults

Pearl Steinzor
Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or influenza across Europe.
Nurse prepares oxygen mask in hospital, conceptual image - Felipe Caparrós - stock.adobe.com.jpeg
October 9th 2024

Identifying Postdischarge Care Needs Among Adults Hospitalized With RSV

Pearl Steinzor
Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.
Blood sample tube for RSV test. | Image credit: JUN LI - stock.adobe.com
October 4th 2024

Adult RSV Hospitalizations: Clinical Characteristics, Risk Factors for Severe Outcomes

Pearl Steinzor
A new study highlights risk factors for hospitalization and severe illness among adults with respiratory syncytial virus (RSV) receiving care through the emergency department.
Vaccine booster concept faded background | MargJohnsonVA - stock.adobe.com
September 30th 2024

Vaccine Hesitancy Persists Despite Understanding Vaccination Effectiveness, Survey Finds

Pearl Steinzor
Survey reveals gaps in vaccination intentions for flu, COVID-19, respiratory syncytial virus, and pneumococcal disease.
Older woman receiving vaccine | Image credit: Melinda Nagy - stock.adobe.com
September 26th 2024

RSV Vaccines Effective in Older Adults in Long-Term Care Facilities

Julia Bonavitacola
A robust antibody response was found in patients in residents of long-term care facilities who were given the respiratory syncytial virus (RSV) vaccine.
Blood sample tube for RSV test. | Image credit: JUN LI - stock.adobe.com
September 17th 2024

New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds

Pearl Steinzor
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, hospitalizations, lost quality of life, and deaths, according to one study.
RSV swab test with negative result | Image credit: MargJohnsonVA - stock.adobe.com
September 4th 2024

RSV Vaccine Shows High Effectiveness Against Hospitalization in Older Adults

Pearl Steinzor
The first real-world study highlights benefits for adults aged 60 years and older who receive the respiratory syncytial virus (RSV) vaccine.
RSV vaccine vial with syringe - Respiratory syncytial virus shot | MargJohnsonVA - stock.adobe.com
August 30th 2024

Sixty Percent of Adults Over 50 Unaware of RSV Risks, Survey Reveals

Pearl Steinzor
A new survey highlights lack of awareness about respiratory syncytial virus (RSV) among older adults, posing increased health risks for those with chronic conditions.
Headquarters of the CDC | Imaged credit: Tada Images - stock.adobe.com
August 7th 2024

Updated ACIP Guidelines: RSV Vaccine for Adults Aged 60 Years and Older

Pearl Steinzor
CDC’s Advisory Committee on Immunization Practices (ACIP) revises respiratory syncytial virus (RSV) vaccination guidelines to prioritize older adults and those at higher risk of severe disease.
Vaccine booster concept faded background | MargJohnsonVA - stock.adobe.com
August 6th 2024

Severe COVID-19 Illness Linked to Prior Respiratory Syncytial Viral Infection, Study Finds

Pearl Steinzor
New research highlights the increased risk of severe COVID-19 in individuals previously infected with respiratory syncytial virus (RSV).
RSV vaccine | Peter Hansen - stock.adobe.com
July 31st 2024

Assessing the Economic Burden of RSV-Associated Hospitalizations Among US Adults

Pearl Steinzor
Researchers estimate the financial impact of respiratory syncytial virus (RSV) in cardiorespiratory hospitalizations using MarketScan data and CDC viral positivity rates.
What We’re Reading: Social Media Regulations; Merck’s Antibody-Based RSV Vaccine; Drug Shortages Hit a New High
July 23rd 2024

What We’re Reading: Social Media Regulations; Merck’s Antibody-Based RSV Vaccine; Drug Shortages Continue

AJMC Staff
Efforts to regulate social media for youth face resistance; MK-1654 meets key goals in mid-to-late stage trial; active drug shortages remain above 300 for sixth consecutive quarter.
pregnant woman with stuffed animal | Image credit: Kostia - stock.adobe.com
July 12th 2024

Nonadjuvanted Bivalent RSV Vaccination Not Associated With Preterm Birth, Study Finds

Pearl Steinzor
No increased risks of preterm birth or perinatal outcomes were identified with maternal vaccination status, according to one study.
A panel of 5 experts on RSV
July 8th 2024

Diagnostic Practices for RSV

Ryan Haumschild, PharmD, MS, MBA Wanda Filer, MD, MBA Marty J. Feltner, PharmD Mary Bridgeman, PharmD, BCPS, BCGP Abby Lynne Singleton, PharmD
Focusing on the diagnosis of RSV, Mary Bridgeman, PharmD, BCPS, BCGP, provides clinical insights on signs and symptoms and testing practices.
RSV_Peter Hansen - stock.adobe.com.jpeg
July 2nd 2024

Which Demographic, Environmental Factors Have Higher Risks for RSV Hospitalization?

Pearl Steinzor
Knowledge on respiratory syncytial virus (RSV) risk factors may help inform public health authorities on high-risk populations, researchers suggest.
A panel of 5 experts on RSV
July 1st 2024

RSV: Risk Factors and How It’s Spread

Ryan Haumschild, PharmD, MS, MBA Wanda Filer, MD, MBA Marty J. Feltner, PharmD Mary Bridgeman, PharmD, BCPS, BCGP Abby Lynne Singleton, PharmD
A panel of experts outline who’s at risk for RSV and how it’s spread, highlighting how transmission can be minimized.
A panel of 5 experts on RSV
July 1st 2024

The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

Ryan Haumschild, PharmD, MS, MBA Wanda Filer, MD, MBA Marty J. Feltner, PharmD Mary Bridgeman, PharmD, BCPS, BCGP Abby Lynne Singleton, PharmD
Focusing on the economic burden of RSV, the panel discusses financial considerations for multiple patient populations, highlighting hospitalization costs and the main drivers of healthcare resource utilization.
Marty J. Feltner, PharmD, an expert on RSV
June 24th 2024

Complications Associated with RSV Infections

Ryan Haumschild, PharmD, MS, MBA Wanda Filer, MD, MBA Marty J. Feltner, PharmD Mary Bridgeman, PharmD, BCPS, BCGP Abby Lynne Singleton, PharmD
Marty J. Feltner, PharmD, provides insights on complications associated with RSV infections and how complications vary for different patient populations.
A panel of 5 experts on RSV
June 24th 2024

Overview of RSV Patient Populations

Ryan Haumschild, PharmD, MS, MBA Wanda Filer, MD, MBA Marty J. Feltner, PharmD Mary Bridgeman, PharmD, BCPS, BCGP Abby Lynne Singleton, PharmD
A panel of experts on respiratory syncytial virus (RSV) introduce themselves and give an overview of patients who are most affected by RSV.
RSV vaccine vial with syringe - Respiratory syncytial virus shot | MargJohnsonVA - stock.adobe.com
June 18th 2024

Simultaneous RSV, Influenza Vaccination Found Safe in Patients With High-Risk Heart Failure

Pearl Steinzor
Vaccination against seasonal influenza and respiratory syncytial virus (RSV) in patients with high-risk heart failure was found safe with low incidence of mild adverse events (AEs).
RSV vaccine | Peter Hansen - stock.adobe.com
June 11th 2024

FDA Approves Expanded Age Indication for RSV Vaccine Arexvy

Pearl Steinzor
The first respiratory syncytial virus (RSV) vaccine has been approved for adults aged 50 to 59 years who are at increased risk.
FDA approval | Image Credit: MargJohnsonVA - stock.adobe.com
May 31st 2024

Moderna Receives FDA Nod for Single-Dose RSV mRNA Vaccine

Cameron Santoro
The FDA approved mRNA-1345, a Moderna vaccine for the treatment of respiratory syncytial virus (RSV). This single-dose vaccine offers protection against lower respiratory tract disease in adults over 60 years, with data suggesting long-term effectiveness.
Boy at doctor's office
August 31st 2023

Airway Narrowing Common in Patients With RSV Acute Bronchiolitis

Julia Bonavitacola
Lung sound analysis was able to confirm airway narrowing in patients with respiratory syncytial virus (RSV) acute bronchiolitis.
Baby
August 25th 2023

Study Finds Newborn Nursery to Be the Optimal Location to Administer Extended Half-Life RSV Antibodies

Julia Bonavitacola
Administering extended half-life respiratory syncytial virus (RSV) antibodies in the newborn nursery would minimize access disparities and ensure optimal uptake, study authors posited.
Lungs
August 18th 2023

Serious Respiratory Symptoms Due to RSV Prevented With Palivizumab

Julia Bonavitacola
Palivizumab may be well tolerated and effective in the prevention of serious respiratory symptoms due to infection with respiratory syncytial virus (RSV).
Person Holding Infant
August 15th 2023

Most US Infants With RSV Were Healthy, Born at Term, Study Finds

Julia Bonavitacola
A recent study found that most infants who required intensive care for respiratory syncytial virus (RSV) were healthy and born at term, indicating that preventive interventions for RSV must target all infants, according to the authors.
Lungs
August 7th 2023

Cough, Shortness of Breath Among Common Manifestations of RSV

Julia Bonavitacola
Results of a new review confirm an association between respiratory syncytial virus (RSV) and wheezing in infants.
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo